Does Medicaid Cover Wegovy? (2026 State Rules, PA Steps & Real Costs)
Published: · Last reviewed:
· Sources: KFF, CMS, FDA, NovoCare, state Medicaid bulletinsSome links on this page are sponsored. We may earn a commission if you use them. That never decides what we recommend or what we cover. Read the full disclosure.
The short answer
Yes — Medicaid can cover Wegovy. But not in most states, and not for weight loss alone.
As of January 2026, KFF reported that 13 state Medicaid fee-for-service programs cover GLP-1 medications for obesity treatment. All of them use prior authorization. The other 37 states plus DC had no fee-for-service obesity GLP-1 pathway in that snapshot.
Here's what most articles miss. Wegovy has three FDA-approved indication categories — chronic weight management, cardiovascular risk reduction in eligible adults with established heart disease, and noncirrhotic MASH liver disease. The cardiovascular and MASH paths fall outside the weight-loss exclusion, which makes coverage mandatory under federal Medicaid drug rebate rules in every state, subject to prior authorization.
The trap most articles bury: The $25 Wegovy commercial savings card excludes all Medicaid enrollees by its official terms. Your real cash-pay floor is $349/month through NovoCare Pharmacy ($199/month for your first two fills through June 30, 2026). The Wegovy tablet starts at $149/month for the 1.5 mg and 4 mg doses.
Verified May 16, 2026
We cross-checked KFF's January 2026 Medicaid GLP-1 analysis, CMS BALANCE Model and Medicare GLP-1 Bridge documentation, Wegovy's current FDA label, NovoCare's posted pricing and savings-offer terms, and the four most recent state Medicaid bulletins for California, Pennsylvania, New Hampshire, and South Carolina.
Does Medicaid cover Wegovy?
Medicaid can cover Wegovy, but the answer depends on three things at once: your state, why your doctor is prescribing it, and which Medicaid plan you're enrolled in. Federal law lets states exclude drugs used for weight loss alone. The same federal law generally requires coverage for medically accepted non-weight-loss indications. Most readers landing on this page have at least one path they didn't know existed.
The three questions that decide your answer
| Question | Why it matters |
|---|---|
| What state are you in? | Each state Medicaid agency sets its own rules for weight-loss drugs. As of January 2026, 13 state Medicaid FFS programs covered GLP-1s for obesity. The remaining 37 states plus DC did not have a fee-for-service obesity GLP-1 pathway. |
| Why was Wegovy prescribed? | Wegovy has three FDA-approved indication categories. One (weight loss) is excludable under federal Medicaid law. The other two (cardiovascular risk reduction, MASH) fall outside that exclusion. Under-21 EPSDT adds a separate medical-necessity path. |
| Are you in fee-for-service Medicaid or managed care? | About 78% of Medicaid enrollees are in comprehensive managed care plans (MCOs), and MCO formularies can be stricter or looser than the state baseline. |
What “covered” actually means
Even in the 13 states that cover GLP-1s for obesity, you still need to clear prior authorization. The pharmacy can still reject your prescription if the PA hasn't been approved. Coverage is a door, not an open one.
What “not covered” actually means
If your state doesn't cover Wegovy for weight loss, that does not automatically mean you're out of options. It means the obesity-only door is closed. You may still have three other doors — cardiovascular, MASH, and EPSDT.
Does Medicaid cover Wegovy for weight loss?
For weight loss alone, Medicaid coverage of Wegovy is optional for states — meaning each state decides — and most states say no. As of January 2026, KFF reported 13 state Medicaid fee-for-service programs cover GLP-1 medications for obesity treatment. That number dropped from 16 the previous October after California, New Hampshire, Pennsylvania, and South Carolina all cut coverage effective January 1, 2026.
Why weight loss is treated differently
Under the Medicaid Drug Rebate Program, there's a short list of drug categories states are allowed to exclude. Drugs “used for weight loss” are on that list. So states can say no to Wegovy for obesity without breaking federal law. That same federal law generally requires coverage of drugs for medically accepted non-weight-loss indications, subject to PA and diagnosis documentation.
The math behind the state cuts
KFF tracked Medicaid GLP-1 prescriptions rising from about 1 million in 2019 to over 8 million in 2024 — an eightfold jump. Gross spending grew from roughly $1 billion to nearly $9 billion. Pennsylvania: GLP-1s went from 5% of total Medicaid drug spending in 2022 to 22% in 2025. The state cut the program and projected $836 million in savings. When states cut Wegovy, it's because the budget broke — not because Wegovy doesn't work.
Which states cover Wegovy through Medicaid in 2026?
As of May 2026, 13 state Medicaid programs cover GLP-1 medications for obesity with prior authorization. Three of those states restrict coverage further. Four states cut coverage effective January 1, 2026. Massachusetts plans a further restriction effective July 1, 2026.
The 13 states with current coverage
Full coverage (with PA)
Delaware · Minnesota · Mississippi · Missouri · North Carolina · Rhode Island · Tennessee · Utah · Virginia · Wisconsin
Restricted coverage (PA + additional criteria)
Kansas · Massachusetts · Michigan (morbid obesity only, with documented failure of other interventions)
Recent state moves you should know about
| State | What changed | When |
|---|---|---|
| California | Medi-Cal Rx no longer covers GLP-1s for weight loss in adults 21+. Wegovy for noncirrhotic MASH continues with the right diagnosis code. Cardiovascular use requires a PA request. EPSDT coverage continues case-by-case for members under 21. | Jan 1, 2026 |
| Pennsylvania | Medicaid ended GLP-1 coverage for overweight/obesity in adults 21+. Under-21 enrollees keep coverage under EPSDT. Coverage for cardiovascular and sleep apnea indications continues with PA. | Jan 1, 2026 |
| New Hampshire | GLP-1 medications no longer covered solely for weight loss. Other FDA-approved indications still covered. | Jan 1, 2026 |
| South Carolina | Wegovy and Saxenda removed from the Medicaid formulary for obesity. | Jan 1, 2026 |
| Michigan | Coverage restricted to morbid obesity only, with documented failure of other weight loss interventions before approval. | Jan 1, 2026 |
| North Carolina | Coverage cut in October 2025, then reinstated December 12, 2025 after the legislative budget cleared. Coverage currently active. | Dec 12, 2025 |
| Massachusetts | Shifted preferred adult GLP-1 from Wegovy to Zepbound; further restriction announced for July 1, 2026. Current enrollees should verify their renewal timeline. | Mar 2026 / Jul 1, 2026 |
Watch list
Rhode Island and Wisconsin were both reported considering new restrictions in late 2025. Connecticut has been discussing ending coverage. Sources: KFF, Stateline, state Medicaid bulletins.
Coverage reach — what “13 states” actually means for real people
19.7%
of adult Medicaid enrollees live in states with an obesity GLP-1 coverage path (~7.8M of 39.5M adults)
80.3%
of adult Medicaid enrollees live in states with no fee-for-service obesity path
~35%
of adult Medicaid enrollees live in states that changed coverage status in the last 12 months
Does Medicaid managed care cover Wegovy differently than fee-for-service?
Sometimes — and it matters, because about 78% of Medicaid enrollees are in comprehensive managed care plans (MCOs). The state's fee-for-service policy is your baseline, but your MCO can have its own formulary, its own PA form, and its own appeal workflow. If your card shows a plan name like Aetna Better Health, Anthem MediBlue, Centene, Molina, UnitedHealthcare Community Plan, or Sunshine Health, you're in managed care. Call that number first.
In some states, the MCO covers drugs the state FFS program doesn't, and the reverse also happens. The state-level answer is your starting point, never your final answer.
Five things to verify with your MCO
- Is the plan using the state Medicaid preferred drug list or its own formulary?
- Does the MCO require its own prior authorization form?
- What documentation does the MCO require for the indication on your prescription?
- Has the formulary been updated in the last 90 days?
- If your prescription is denied at the pharmacy, who handles the appeal — the state Medicaid agency or your MCO?
Does your diagnosis change Medicaid Wegovy coverage?
Yes — and this is the most important thing on this page. Wegovy has three FDA-approved indication categories, not one. Only one (weight loss) can be excluded from Medicaid under federal law. The other two trigger mandatory coverage in every state, subject to PA. EPSDT adds a separate Medicaid medical-necessity pathway for members under 21.
Quick crosswalk: FDA indication × Medicaid coverage rule
| Use case | Wegovy FDA label | Medicaid coverage rule | PA likely? |
|---|---|---|---|
| Weight loss only (BMI ≥30, or ≥27 with comorbidity) | Approved for chronic weight management in adults and adolescents 12+ (injection); approved for adult weight reduction (tablet) | State-optional. As of Jan 2026, 13 states cover it for obesity. | Yes — in every covered state |
| Cardiovascular risk reduction | Approved for adults with established CVD and obesity or overweight (injection and tablet) | Mandatory under federal Medicaid drug rebate rules. State weight-loss exclusion does not apply. | Yes — with CV documentation |
| Noncirrhotic MASH with F2–F3 fibrosis | Approved for noncirrhotic MASH in adults (injection only; tablet not approved for MASH) | Mandatory under federal Medicaid drug rebate rules. | Yes — with MASH documentation |
| Under 21, medically necessary | Injection approved for adolescents 12+ with obesity. Tablet not approved for pediatric use. | EPSDT medical-necessity path — case-by-case review, plan cannot apply blanket exclusion to a minor. | Yes — and appeal must cite EPSDT if denied |
Cardiovascular risk reduction (FDA-approved March 2024)
If you have established cardiovascular disease — a prior heart attack, a prior stroke, or documented coronary artery disease — and your BMI is at least 27, Wegovy is FDA-approved to lower your risk of another major cardiovascular event.
Important precision: high blood pressure alone does not equal established cardiovascular disease for this indication. The label requires a documented prior MI, stroke, or coronary artery disease.
Real-world example
A 54-year-old Medicaid enrollee in Pennsylvania with a BMI of 32 and a heart attack in 2023. After January 1, 2026, Pennsylvania doesn't cover Wegovy for obesity. But Pennsylvania does still cover it for cardiovascular risk reduction with PA — because that's federal law, not state choice. Same patient, different door, different answer.
Common ICD-10 codes: I25.10 (atherosclerotic heart disease), I21.x (recent MI), I63.x (cerebral infarction), with E66.x (obesity)
MASH liver disease (FDA-approved August 2025)
If you have noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced liver fibrosis (stage F2–F3), Wegovy injection is FDA-approved to treat that condition. Wegovy is currently the only GLP-1 with this indication. Because it's a liver disease indication — not weight loss — federal Medicaid drug rebate rules require coverage.
California's official Medi-Cal Rx notice explicitly confirms Wegovy for MASH continues to be covered after the January 2026 obesity cut, if the prescriber submits the appropriate diagnosis code.
Formulation note
The FDA-approved Wegovy tablet is not labeled for MASH — only the injection is. If your prescriber wants to use the MASH pathway, the prescription needs to be for Wegovy injection.
Common ICD-10 codes: K75.81, K76.0. Documentation typically needed: liver biopsy or imaging confirming F2–F3 fibrosis.
Under age 21 — EPSDT
If you're under 21 and on Medicaid, you have an additional federal protection most people don't know about. EPSDT requires Medicaid to cover medically necessary treatment for enrollees under 21, even when that treatment is excluded for adults. A plan cannot apply a blanket “we don't cover weight loss drugs” rule to a minor. Each request must be evaluated case-by-case for medical necessity.
Wegovy injection is FDA-approved for adolescents 12 and older with obesity. The Wegovy tablet is not approved for pediatric use. Pennsylvania's January 2026 obesity coverage cut explicitly preserved under-21 access for exactly this reason. If your child has been denied Wegovy on Medicaid, the appeal should cite EPSDT directly.
Type 2 diabetes — ask for a different drug
Wegovy is not FDA-approved for type 2 diabetes. The semaglutide brand approved for diabetes is Ozempic — same active ingredient, different brand, different label. Medicaid coverage is generally required for diabetes-indicated GLP-1s, subject to formulary rules and PA.
Not sure which path fits you?
Find your Wegovy coverage path in 60 seconds
Take the free GLP-1 path quiz →Medicaid prior authorization for Wegovy: what your doctor actually has to submit
Every state Medicaid program that covers Wegovy requires prior authorization (PA), and PA is also expected for the cardiovascular, MASH, and EPSDT pathways. A PA is a documentation packet your doctor's office sends to your Medicaid plan before the pharmacy can fill the prescription. A lot of denials are PA denials, and PA denials are often fixable with better documentation.
Standard Medicaid PA requirements for Wegovy (obesity indication)
- ✓Current measured BMI within the last 30 days (≥30, or ≥27 with at least one weight-related comorbidity)
- ✓Documented weight-related comorbidities (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea)
- ✓6+ months of documented lifestyle intervention (diet, exercise, supervised program records)
- ✓Prior weight-loss medication trial history (in step-therapy states)
- ✓Recent labs: A1C and lipid panel
- ✓Clinical rationale for why Wegovy specifically (versus alternatives)
For renewal after the first 3–6 months, most states require at least 5% documented weight loss to keep coverage active.
PA documentation by indication
| Indication | BMI requirement | Additional documentation needed | Common ICD-10 codes |
|---|---|---|---|
| Obesity / weight management | ≥30, or ≥27 with comorbidity | 6+ months of lifestyle intervention, comorbidity records, prior medication trials in step-therapy states | E66.9, E66.01, Z68.3x |
| Cardiovascular risk reduction | ≥27 with overweight or obesity | Documented prior MI, stroke, or established CAD; cardiology records | I25.10, I21.x, I63.x, with E66.x |
| Noncirrhotic MASH (F2–F3) | Not BMI-driven | Liver biopsy or imaging confirming F2–F3 fibrosis; MASH/NASH diagnosis | K75.81, K76.0 |
| EPSDT (under 21) | Per treating clinician | Letter of medical necessity; growth records; comorbidity documentation | Indication-specific |
What to bring to your doctor's appointment
- →Your full weight history (last 2–3 years if possible)
- →Every prior weight-loss attempt (program names, dates, why each one ended)
- →Past prescription weight-loss medications you tried, with results
- →Most recent A1C and lipid panel
- →Any cardiovascular event history (dates, diagnoses)
- →Any MASH/NASH or liver disease documentation
- →Your insurance card with the back-of-card phone number for the pharmacy benefit
- →Your Medicaid managed care plan name (if applicable)
What to ask your Medicaid plan before your doctor submits
Before your doctor's office submits a Wegovy PA, call your Medicaid plan directly and ask for the exact rules in writing. A lot of denials happen because nobody asked first. Federal Medicaid rules allow you to request formulary status and PA criteria. The plan has to tell you.
The script (read this out loud, change the bracketed parts)
“Hi. I'm a Medicaid member and my member ID is [NUMBER]. I'm asking about Wegovy. Three questions:
One — is Wegovy on my plan's preferred drug list right now, and for which indications?
Two — what does my prescriber need to include in the prior authorization for [obesity / cardiovascular risk reduction / MASH / my child's case under EPSDT]?
Three — can you email or mail me the prior authorization criteria in writing, and the name of the person I just spoke with?”
Write down the date, the name, and what they said. If they refuse to send the criteria in writing, ask for a supervisor. You're entitled to this information.
If your state recently changed coverage (CA, PA, NH, SC, MI, MA)
“Was the policy on Wegovy changed in the last 12 months? Is there a continuation-of-therapy provision for members who were already on Wegovy before the change? Are transition fills available?”
What to do if Medicaid denies Wegovy
A Medicaid Wegovy denial is the start of an appeal, not the end of the road. Appealing is often worth considering when the denial reason can be answered with better documentation, a corrected indication, a formulary exception request, or medical-necessity evidence. The first thing you have to do is identify why you were denied.
Step 1: Get the denial reason in writing
Don't rely on what a pharmacy clerk says at the counter. Call your Medicaid plan and request the formal denial notice. By law, it has to include the reason, the appeal deadline, and your hearing rights.
Step 2: Match your response to the denial reason
| Denial reason | What it really means | Your best next step |
|---|---|---|
| Plan exclusion — not covered for weight loss | Your state Medicaid does not cover Wegovy for obesity | Check whether the cardiovascular, MASH, or EPSDT pathway applies. If yes, resubmit under that indication. If no, switch to a cash-pay route. |
| Prior authorization not approved | Documentation didn't meet plan criteria | Resubmit with the missing documentation. Request a peer-to-peer review with the plan's medical director. |
| Not on formulary | Wegovy isn't on the preferred drug list | Request a formulary exception or coverage exception. Submit a letter of medical necessity. |
| Only covered for [other indication] | Your prescription used the wrong indication | Re-evaluate which FDA-approved indication actually fits your chart and resubmit. |
| Step therapy required | You have to try other drugs first | Document why prior drugs failed or aren't appropriate. Some states allow medical-necessity overrides. |
Step 3: Escalate in the right order
- 1Internal appeal. Check your denial notice for the deadline. In California, you generally have 90 days from the Notice of Action date to request a State Hearing. Include updated clinical documentation, a letter of medical necessity, and direct responses to each reason given.
- 2Peer-to-peer review. Your doctor can request a phone call with the plan's medical director. This is short, free, and often successful when documentation was the issue.
- 3State fair hearing. If internal appeals fail, you have the right to a hearing through your state Medicaid agency. Deadlines vary by state — your denial notice controls.
- 4External review. Depending on your state, an independent third party can review after internal appeals are exhausted.
Special escalation for under-21 enrollees: cite EPSDT
If you're appealing a Medicaid denial for someone under 21, write EPSDT into the first paragraph of the appeal. A plan cannot apply a blanket “we don't cover weight loss drugs” exclusion to a minor. Each case must be evaluated individually for medical necessity. This is federal law, not state preference.
If Medicaid won't cover Wegovy: real costs and real options
When Medicaid is fully closed for Wegovy in your case, you have a handful of real cash-pay routes. What you cannot use as a Medicaid enrollee: the $25 commercial savings card or Novo Nordisk's Patient Assistance Program. Both exclude government program beneficiaries by their official terms.
The honest pricing snapshot (verified May 16, 2026)
| Route | Cash price | Medicaid enrollees? | Notes |
|---|---|---|---|
| Wegovy retail list price | ~$1,349/month | N/A | List price |
| NovoCare Pharmacy — intro offer | $199/month for first 2 fills | ✅ Yes | Pen 0.25 mg & 0.5 mg, through June 30, 2026 |
| NovoCare Pharmacy — ongoing (pen 0.25–2.4 mg) | $349/month | ✅ Yes | Manufacturer-direct, no insurance billing |
| NovoCare Pharmacy — Wegovy HD (7.2 mg pen) | $399/month | ✅ Yes | Higher-dose pen, FDA-approved for weight loss and long-term maintenance |
| NovoCare Pharmacy — Wegovy tablet (1.5 mg, 4 mg) | $149/month | ✅ Yes | 4 mg offer ends Aug 31, 2026, then $199/month. Higher tablet doses priced separately. |
| Sesame Care — Success by Sesame | From $59/month with annual subscription; medication separate | ✅ Yes (cash-pay) | Wegovy tablets from $149/month and pens from $199/month (first 2 fills), then $349/month |
| Ro Body program | $39 first month, then $149/month; medication separate | ✅ Yes (cash-pay) | Carries Zepbound and Foundayo at NovoCare-equivalent pricing. Verify current Wegovy availability. |
| Wegovy $25 commercial savings card | $25/month | ❌ NO | Novo's offer terms exclude all government program beneficiaries including Medicaid |
| Novo Nordisk Patient Assistance Program (PAP) | N/A for Wegovy | ❌ NO | PAP excludes Medicaid enrollees by its eligibility rules |
Sources: NovoCare Pharmacy pricing chart and savings offer terms, Sesame Care Success by Sesame program page, Ro Body pricing page, Novo Nordisk PAP eligibility page. Verified May 16, 2026.
Provider-stated vs. verified — the affiliate trust table
| Provider | FDA-approved meds listed | Membership/visit fee | Insurance support? | Medicaid billed? | Best fit |
|---|---|---|---|---|---|
| Sesame Care | Wegovy, Ozempic, Mounjaro, Zepbound, Foundayo, Saxenda (per Sesame's pages) | Success by Sesame from $59/mo annual | Limited (cash-pay focused) | No | Want Wegovy by name with provider choice and clear cash pricing |
| Ro Body | FDA-approved GLP-1s including Zepbound and Foundayo; verify current Wegovy availability | $39 first month, $149/mo ongoing, $74/mo with annual prepay | Yes — insurance concierge and free GLP-1 coverage checker | No | Want structured program and insurance navigation, open to Zepbound or Foundayo |
Sesame Care — best match if you want Wegovy specifically
Sesame's GLP-1 lineup includes Wegovy, Ozempic, Mounjaro, Zepbound, Foundayo, and Saxenda. The Success by Sesame program is as low as $59/month with an annual subscription, with medication priced separately. You pick your provider.
Sponsored link. We may earn a commission.
Ro Body — best match if you'd consider Zepbound or Foundayo
Ro Body is built around FDA-approved GLP-1 access with insurance support. Ro states it carries Zepbound (tirzepatide) and Foundayo (orforglipron) at the same cash pricing as NovoCare, LillyDirect, and TrumpRx. Membership is $39 for the first month, then $149/month or as low as $74/month with an annual plan paid upfront. Ro includes an insurance concierge and a free GLP-1 coverage checker.
Sponsored link. We may earn a commission.
Who should NOT sign up for any cash-pay route yet
- → If your state Medicaid covers Wegovy and you haven't tried the PA process yet, pursue PA first. Cash-pay is plan B.
- → If you have established cardiovascular disease, MASH, or you're under 21 and haven't tried those pathways, go try those first. Mandatory coverage paths beat cash-pay every time.
- → If $74–$349/month isn't sustainable for your budget, do not sign up. Financial stress from an unsustainable subscription is worse than waiting.
A note on compounded semaglutide
Compounded medications are not FDA-approved products and are not the same as FDA-approved Wegovy. Their availability depends on federal compounding rules, pharmacy status, shortage status, and patient-specific prescribing. Because this page is specifically about Wegovy — the FDA-approved brand — we don't feature compounded options here.
Will the BALANCE Model or TrumpRx change Medicaid Wegovy coverage?
Possibly — but only in states that voluntarily join, and never automatically for any individual patient. The CMS BALANCE Model is a voluntary program for state Medicaid agencies. CMS says state agencies can join beginning May 2026 through January 1, 2027. CMS also says the model does not guarantee coverage for any individual.
What BALANCE could change
- → Negotiated drug prices (Wegovy, Zepbound, Ozempic, Foundayo included)
- → Standardized PA criteria across participating states
- → Manufacturer-funded lifestyle support for enrolled patients
- → States can start with FFS, bring MCOs in over time
What BALANCE does NOT change
- → Does not require any state to participate
- → Does not change current coverage in non-participating states
- → Does not remove prior authorization
- → Does not guarantee coverage for any individual enrollee
A word on TrumpRx
TrumpRx is a federal website that routes self-pay shoppers to discounted GLP-1 pricing negotiated with manufacturers. It's not a Medicaid coverage program. For Medicaid enrollees, BALANCE is the relevant program — TrumpRx pricing is unlikely to be lower than what you'd find through NovoCare Pharmacy direct.
Medicare context — for readers comparing programs
Medicare Part D can cover Wegovy for medically accepted non-weight-loss indications, such as cardiovascular risk reduction in eligible adults. CMS says the Medicare GLP-1 Bridge will run from July 1, 2026 through December 31, 2027 for eligible Part D beneficiaries. Coverage for weight loss alone remains generally excluded under federal law. The Medicare Part D BALANCE Model launch has been indefinitely delayed per recent reporting.
Quick Wegovy safety primer (read this before any path)
Wegovy is a prescription medication with real contraindications and side effects. This page is about coverage, not medical advice — but you should know what to ask your prescriber about before starting any GLP-1. Source: current FDA prescribing information for Wegovy (semaglutide).
Who should not take Wegovy
- → Personal or family history of medullary thyroid carcinoma (MTC)
- → Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- → Known serious allergic reaction to semaglutide or any Wegovy ingredient
Warnings your prescriber should review
- → Pancreatitis; Gallbladder disease
- → Low blood sugar (if also taking insulin or sulfonylureas)
- → Kidney injury; Severe gastrointestinal reactions
- → Hypersensitivity reactions; Increased heart rate
- → Diabetic retinopathy complications
- → Pulmonary aspiration risk during general anesthesia
Most common side effects from the Wegovy label: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, bloating, belching, and others. Read the full prescribing information before starting.
Methodology — how we verified this page
We used a primary-source hierarchy. Every coverage claim is sourced. Every price is dated. Every state status is cross-checked against at least two independent sources before publication.
What “last verified” means
The date at the top of this page reflects the most recent day on which we re-checked every state's coverage status, NovoCare's current pricing and savings-offer terms, Ro's and Sesame's current GLP-1 program pricing, and the BALANCE Model timeline. We re-verify monthly.
Source hierarchy (priority order)
- FDA-approved prescribing information for Wegovy — for all indication, contraindication, and warning claims
- CMS and Medicaid.gov policy pages — for federal program rules (Medicaid Drug Rebate Program, EPSDT, BALANCE Model)
- KFF Medicaid GLP-1 analyses — for aggregate state-level coverage trends (most recent: KFF, January 2026)
- State Medicaid preferred drug lists, pharmacy bulletins, and member notices
- NovoCare and Novo Nordisk official pages — for pricing and savings-offer terms
- Provider pages — for telehealth provider pricing and medication availability
Corrections policy
State Medicaid coverage moves fast. If you see a state formulary, PDL, or Medicaid bulletin that contradicts something on this page, send it to us. We update with primary-source documentation only.
Frequently asked questions
Does Medicaid cover Wegovy for weight loss?▼
Which states cover Wegovy through Medicaid in 2026?▼
Does Medicaid cover the Wegovy pill?▼
Does Medicaid cover Wegovy HD (7.2 mg)?▼
How much does Wegovy cost with Medicaid?▼
What is the BMI requirement for Medicaid to cover Wegovy?▼
Why doesn't Medicaid cover Wegovy in most states?▼
Can I appeal a Medicaid Wegovy denial?▼
Does Medicaid cover Wegovy for cardiovascular disease?▼
Does Medicaid cover Wegovy for MASH?▼
Can my child or teenager get Wegovy through Medicaid?▼
Can I use the Wegovy $25 savings card if I have Medicaid?▼
Does Novo Nordisk have a Patient Assistance Program for Wegovy?▼
Will the BALANCE Model expand Medicaid Wegovy coverage in my state?▼
Does Medicare cover Wegovy?▼
Do Medicaid managed-care plans follow the same rules as state Medicaid?▼
Still not sure which GLP-1 path is right for you?
Take the free 60-second GLP-1 matching quiz
No account required. Routes you to the next step most likely to actually work.